Compound Effects on Calcium Transients in Beating Axiogenesis Cor.4U Human iPS Cell-Derived Cardiomyocytes

The assessment of cardiotoxicity is important in the early stages of drug discovery to enable elimination of potentially toxic compounds from further development. This is critical to reduce the inefficiencies and high costs associated with compounds that fail during cardiac safety assessment. There is a growing need for highly predictive in vitro cardiotoxicity assays that use biologically relevant cell-based models and are
suitable for high-throughput screening.